Figure 6: Cotreatment with ERK inhibitor and CHK2 inhibitor II results in decreased tumour growth in a xenograft model.
From: Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma
(a) 28 mice bearing s.c. tumours of SUDHL6 cells were divided into 4 groups (vehicle versus ERK inhibitor versus CHK2 inhibitor II versus combination), with 7 mice each. Representative mice were photographed before death to visually demonstrate tumour growth. (b) The average tumour volume of each group (n=7) with s.d. is shown as a function of time. P values were calculated using a Student t-test and statistical significance was determined when a P value less than 0.05 was attained. *P<0.05; **P<0.01 versus single treatments. (c) At the moment of mice death, xenograft tumours were excised, and the pooled protein extracts randomly from three mice of each group was subjected to western blot analysis using the indicated antibodies. (d) Tumour tissue sections were subjected to immunochemistry for Ki67 expression (original magnification, X400) and TUNEL staining (original magnification, X600).
